Pollution by the pharmaceutical, healthcare, and agricultural sectors is driving the development of 'superbug' strains of bacteria that have become resistant to every know
A consortium of industry and academic groups – led by Johnson & Johnson's pharma division Janssen – has been set up to tackle the environmental impact of
As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas